The definitive source for pharmaceutical cold chain compliance
Regulatory updates, FDA enforcement actions, and industry analysis covering the pharmaceutical wholesale distribution supply chain.
FDA issued a warning letter to New Life Pharma for CGMP violations and inspection refusal. The case illustrates critical upstream compliance risks for wholesale distributors conducting supplier due diligence under DSCSA.
UPS implemented a $1.25 per-pound surcharge on international pharmaceutical cold chain shipments effective January 13, 2025. Approximately 340 wholesale drug distributors in ColdChainCheck's directory face direct cost exposure from the fee, which applies to all temperature-controlled packages between 2°C and 8°C.
USTR's April 2026 tariff exemption for Indian generics requires FDA cGMP compliance and U.S. manufacturing commitments by 2028. Wholesale distributors must now verify manufacturer exemption status quarterly or face retroactive tariff liability on already-distributed products.
FDA's April 2026 AMSPA briefing clarifies that wholesale drug distributors supplying medspas must comply with full DSCSA traceability requirements — including ATP verification and EPCIS data exchange — for all prescription drugs used in aesthetic medicine. The briefing follows counterfeit botulinum toxin seizures and identifies three compliance gaps observed in Q1 2026 inspections.
DSCSA T3 requirements take effect November 27, 2026, mandating serial number-level Transaction Information, Transaction History, and Transaction Statements for all wholesale drug distributors. ColdChainCheck data shows only 2.2% of tracked distributors demonstrate public compliance signals beyond basic FDA registration.
+72 more — switch to the Regulatory Updates tab to see all.
Seven FDA drug recalls issued in April 2026 for microbial contamination and quality failures. Four Class I recalls involve *Burkholderia cepacia* in sterile injectables requiring immediate distributor action under 21 CFR 7.53.
Teva Pharmaceutical issued four FDA recalls in Q1 2025 affecting generic drug products distributed nationwide. Wholesale distributors face immediate DSCSA quarantine and state notification obligations for affected inventory.
DOJ sues Louisiana distributor Morris & Dickson for alleged failure to report suspicious opioid orders under the Controlled Substances Act. First major federal enforcement action since 2021 DEA guidance took effect.
FDA issued a warning letter to Chemco Corporation on January 15, 2025, citing CGMP equipment maintenance violations that resulted in adulterated drug products. Wholesale distributors conducting supplier qualification should review the cited deficiencies as compliance signals during vendor assessment.
+81 more — switch to the FDA Alerts tab to see all.
AHA and ASHP petition FDA to restrict insurer-mandated white bagging for specialty drugs, citing cold chain and DSCSA compliance gaps. ColdChainCheck data shows only 4.9% of tracked distributors hold NABP accreditation—raising verification challenges for hospitals.
WPRX, an Illinois-based wholesale drug distributor, reports 98.7% DSCSA serialization verification accuracy across 47,000 monthly units. This case study reveals the infrastructure, workflow changes, and exception handling protocols required for wholesale distributors to meet enhanced drug supply chain security requirements.
The November 27, 2024 DSCSA interoperability deadline exposed widespread system failures across wholesale drug distributors. ColdChainCheck data shows only 4.9% of tracked entities hold NABP accreditation — a proxy for early serialization infrastructure adoption.
Morris & Dickson's acquisition of Prodigy Health Supply marks the second major specialty drug distribution consolidation in six months, driven by DSCSA compliance costs. ColdChainCheck data shows entities with fewer than 30 state licenses face structural disadvantage as pharmaceutical wholesale consolidation accelerates.
+12 more — switch to the Reactions tab to see all.
FDA inspectors request the same eight documents within the first hour of wholesale distributor inspections. ColdChainCheck data shows only 63 entities (4.9%) hold NABP accreditation indicating continuous audit readiness. Facilities producing documents immediately reduce inspection time by 4-6 hours.
The February 2025 counterfeit Viagra indictment exposes documentation gaps in generic drug sourcing that persist despite DSCSA requirements. Analysis of 1,275 tracked distributors reveals how international supply chain verification failures bypass standard trading partner qualification.
The FDA extended DSCSA enforcement discretion through November 2024 for VRS onboarding, ATP-exempt product handling, and saleable returns verification. ColdChainCheck data shows 1,275 tracked distributors averaging 51/100 compliance scores, with only 5% holding NABP accreditation.
NABP's UMPJE program allows wholesale drug distributors to streamline multi-state licensing through reciprocal recognition. As of March 2025, 17 states participate. ColdChainCheck data shows 847 entities (66%) operate in three or more states and could benefit from portability.
+50 more — switch to the Explainers tab to see all.
News articles are generated from public regulatory sources and reviewed for accuracy. Always verify details directly with the relevant agencies.